SCHEMBL7942016

SCHEMBL7942016

CSc1ccc(C(=O)Nc2cccc(CNc3cccnc3N)c2)nc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 9/20 0.69
NPC1 O15118 2/20 0.47
RAB9A P51151 1/20 0.47
GRM4 Q14833 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KDR P35968 2/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
HDAC3 O15379 1/20 0.41
NCOR1 O75376 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
MAPT P10636 2/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7942380 0.88 BACE1 (0.74) BACE1NPC1RAB9AGRM4SMN1; SMN2
SCHEMBL7933424 0.87 BACE1 (0.73) BACE1GRM4SMN1; SMN2KDRMEN1
SCHEMBL7944708 0.86 BACE1 (0.52) BACE1NPC1RAB9AGRM4SMN1; SMN2
SCHEMBL7944661 0.86 BACE1 (0.71) BACE1GRM4KDRAURKAAURKB
SCHEMBL7933183 0.86 BACE1 (0.71) BACE1GRM4KDRHDAC3NCOR1
SCHEMBL7944667 0.85 BACE1 (0.70) BACE1AURKAAURKB
SCHEMBL7940965 0.85 BACE1 (0.70) BACE1GRM4HDAC3NCOR1HDAC1
SCHEMBL7932681 0.85 BACE1 (0.78) BACE1GRM4MAPTAURKAAURKB
SCHEMBL7941334 0.84 BACE1 (0.78) BACE1NPC1RAB9ASMN1; SMN2HDAC3
SCHEMBL7933218 0.84 BACE1 (0.50) BACE1NPC1RAB9AGRM4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885NPC1 431/4885RAB9A 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.